References
- Avastin® (bevacizumab) prescribing information. Genentech, Inc; 2021. [cited 2021 Sep 5]. Available from: https://www.gene.com/download/pdf/avastin_prescribing.pdf
- Avastin® (bevacizumab). Summary of product characteristics. Roche Pharma AG. Germany: Grenzach-Wyhlen; 2012. [cited 2021 Sep 5]. Available from: https://www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_en.pdf
- Giuliani J, Fiorica F, Albanese V, et al. Financial toxicity and cancer treatments: help from biosimilars - the explanatory case of bevacizumab. Eur J Cancer. 2021;143:40–42.
- Casak SJ, Lemery SJ, Chung J, et al. FDA’s approval of the first biosimilar to bevacizumab. Clin Cancer Res. 2018;24(18):4365–4370.
- Melosky B, Reardon DA, Nixon AB, et al. Bevacizumab biosimilars: scientific justification for extrapolation of indications. Future Oncol. 2018;14(24):2507–2520.
- US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product. 2015. https://www.fda.gov/media/82647/download
- World Health Organization, Expert Committee on Biological Standardization. Guidelines on evaluation of similar biotherapeutic products (SBPs). 2009. [cited 2021 Sep 5]. Available from: https://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf
- Bevacizumab: clinical pharmacology/TOX review. [cited 2021 Sep 5]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/STN-125085_Avastin_BioPharmr.pdf
- European Medicines Agency. Committee for medicinal products for human use. Guideline on similar biological medicinal products containing monoclonal antibodies-non-clinical and clinical issues; 2012. [cited2021 Sep 5]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-monoclonal-antibodies-non-clinical_en.pdf
- European Medicines Agency. Guideline on similar biological medicinal products. 2014. [cited 2021 Sep 5]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-rev1_en.pdf
- MHLW. Guidelines for the quality, safety and efficacy assurance of follow-on biologics (in Japanese). Yakshoku shinsahatu 0304007. 2009 March 4.